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S_..ary The immunohistochemical expression of tenascin was examined in the normal adult mucosa of the
stomach, primary tumours and lymph node metastases of gastric cancer patients. In normal gastric tissue
tenascin was expressed in the muscularis mucosae, musclaris propnra and vessel walls, however it was not
expressed in either the mucosal connective tissue or the stromal tissue in the submucosal layer. In gastric
cancer, tenascin was expressed in 35 of 85 primary tumours, and in 8 of 25 metastases in lymph nodes.
Tenascin was located in the fibrous stroma surrounding foci of cancer. The expression of tenascin in the
primary tumour did not correlate with the depth of invasion, lymph node metastasis or prognosis. Tenascin
appears during the process of either malignant transformation or tumour progression in gastric cancer, and
the positive expression of tenascin may be useful as a stromal marker for the early detection of gastric cancer.
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Tenascin is a glycoprotein component of the extracellular
matrix with a six-armed macromolecular structure of a
disulphide-bonded oligomer (Chiquet-Ehrismann et al.,
1986), consisting of three isoforms of the molecules with a
molecular weight of 190, 200, 230 kDa (Chiquet-Ehrismann
et al., 1991). Tenascin is synthesised by fibroblasts and glial
cells (Erickson and Bourdon, 1989), and was initially
detected as a marker for tendon and muscle morphogenesis
in chicks (Chiquet and Fambrough, 1984; Chiquet-
Ehrismann et al., 1986). Recent studies have demonstrated
the appearance of tenascin during fetal development in
organs such as the gut (Aufderheide and Ekblon, 1988) and
kidney (Aufderheide et al., 1987), as well as in the stromal
tissues of benign and malignant tumours (Mackie et al.,
1987; Erickson and Lightner, 1988; Erickson and Bourdon,
1989; Vollmer et al., 1990; Natali et al., 1990, 1991; Sakakura
et al., 1991; Shoji et al., 1992; Sakai et al., 1993; Soini et al.,
1993a,b; Ramkissoon et al., 1994). However, in normal adult
tissue, tenascin is only slightly expressed or is restricted to a
small range of structures. Therefore, tenascin may have an
oncofetal potential and thus may play an important role in
the mesenchymal cell interaction implicated in the local
infiltrative growth and metastasis of human neoplasms.
Since little is known about the molecular interaction of
epithelial cells and tenascin during neoplastic transformation,
tumour invasion and metastasis in gastric cancer, we studied
the expression of tenascin in normal stomach tissue, gastric
carcinomas and metastatic gastric carcinoma in lymph nodes
using immunohistochemical techniques.
Materals and method
Tissue specimens
We studied 85 gastric cancer patients who had been sur-
gically treated in the Department of Surgery at Sawara Hos-
pital between 1984 and 1986. The patients' ages ranged from
37 to 83 years (mean 64 years). There were 48 men and 37
women. Of these patients, 31 were diagnosed as having
advanced gastric cancer, which is defined as that extending
into or beyond the muscle layer, and 54 were diagnosed as
having early gastric cancer, which is defined as that confined
to the mucosa or submucosa, regardless of the presence or
absence of lymph node metastasis. Of the 54 patients with
early gastric cancer, 24 showed tumour invasion confined to
the mucosa. Tissue specimens were obtained from all 85
primary gastric cancers, and lymph node specimens with
metastatic tumour were selected from 25 cases. The metas-
tatic tumours in each lymph node measured more than 5 mm
in diameter. Normal tissue specimens were selected from 30
of the resected specimens at sites distant from the carcinoma,
avoiding areas affected by histological gastritis or intestinal
metaplasia.
Histological examination and inmunohistochemical procedures
All resected specimens were fixed in 10% formalin and
routinely processed for paraffin embedding. In this study 1-3
tissue blocks were selected in each case to include the largest
diameter of the tumours in both primary and metastatic
lesions. Five-micron-thick sections made from each block
were stained with haematoxylin and eosin. The gastric car-
cinomas were classified into two types with regard to the
degree of glandular formation: differentiated type (intestinal,
expanding and well-differentiated type, characterised by
origin from intestinal metaplasia) and undifferentiated type
(diffuse, infiltrated and poorly differentiated type, charac-
terised by origin from proper gastric gland) (Lauren, 1965;
Nakamura et al., 1968; Ming, 1977; Sugano et al., 1982). All
pathological diagnoses and classifications were based on the
TNM classification of the stomach, as confirmed by the
International Union Against Cancer (Hermanek and Sobin,
1987).
Five micron sections were deparaffiised and washed in
phosphate-buffered saline (PBS). After treatment with 3%
hydrogen peroxide, the sections were incubated at 4 C over-
night with monoclonal antibody to tenascin (DB7 1:200,
Biohit Helsinki, Finland). The sections were treated with
anti-mouse IgG-biotin complex (Vector Laboratories, CA,
USA) followed by avidin-peroxidase complex and then were
stained with 3, 3'-diaminobenzidine (DAB) solution with
0.15% hydrogen peroxide. All sections were briefly counters-
tained with Mayer's haematoxylin. For negative controls,
sections were incubated with non-immune rat serum (1:1000
dilution) instead of the primary antibody. Distinct staining
for tenascin in normal tissue and stromal tissue in the
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tumours was scored as positive (+). Cases with absent tenas-
ci staining in the normal tissue or the stromal tissue in the
tumours were scored as negative (-). Staining of tenasan in
the musculais mucosae, musculais propria or vessel walls
was not regarded as positive.
Res
Table I summarises the expression of tenascin in the normal
tissue of the stomach, pimnary tumours and lymph node
metastases in the gastric cancer patients. In the normal tissue,
the muscularis mucosae, muscularis propria and vessel walls
showed positive expression of tenascn. However, tea
was not exp d in the mucosa or the submucosal connec-
tive tissue. In gastric cancer, tenascin was expressed in 41%
(35/85) of the primary tumours and in 32% (8/25) of the
metastaic tumours in the lymph nodes. Tenascin was located
mainly in the fibrous stroma surrounding the malignant cells
or tubules (Figure 1). Tenascin was also seen in ve:ssel walls
and any normal gastric smooth muscle present in the section.
Tale I The expression of tenascin in the normal mucosa, primary
tumours and metastatic tumours of lymph nodes
Negative (%) Positiwe (%)
Normal mucosa 30 (100) 0
Primary tumour 50 (59) 35 (41)
Metastatic tumour 17 (68) 8 (32)
Table II summarse the expression of tenascin according
to the dinicopathological factors. Tenascin was exp in
46% (16/35) of the differentiated carcinomas and 38% (19/
50) ofundifferentiated carcinomas. The positive expron of
tenascin did not depend on the degree of tumour
differentiation. Tumours of undifferentiated type usually
showed a rich fibrous stroma, however the intensity of tenas-
cm staining was stronger in the differentiated tumours. When
the expression of tenascn was compared between the patients
with tumour invasion within and beyond the submucosal
layer, no statistical difference was observed. Furthermore, in
the 54 patients with early gastri cancer, a positive eexpression
of tenascin was found in 45.8% (11/24) of patients with
intramucosal invasion and 40.0% (12/30) of patients with
submucosal invasion, there being no statistical difference.
The expression of tenascin regarding the patient's sex,
tumour location and lymph node status was studied, but no
statistical differences were observed when the expression of
tena was compared in tumours separated on the basis of
these clinicopathological factors.
The expresson of tenasin in primary tumours was com-
pared with that in metastatic tumours in lymph nodes in 25
cases (Table Ill). Of ten cases with tenascm-positive expres-
sion in the primary tumour, five cases also showed positive
expression in the metastatic tumour in lymph nodes; how-
ever, the five other cases showed negative expression in the
metastatic tumour in lymph nodes. Three further cases with
positive expression of tenascin in the lymph node metastases
did not show positive expression in the primary tumours.
The survival curves are shown with respect to the expres-
sion of tenascin in Figure 2. The 5 year survival rates were
61% with a positive expression of tenascin and 72% with a
negative expression of tenasin. No statistal difference in
survival was observed.
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Fugue 2 The survival curves for patients with gastric cancer
according to the expression of tenascin. There were 35 patients
with positive expression of tenascin (dark line) and 50 patients
with negative expression of tenascin (light line). There was no
statistical difference in survival between the two groups.
appears in the stromal tissues of various human neoplasms.
such as breast cancer (Mackie et al., 1987; Shoji et alt, 1992).
colon cancer (Sakai et al.. 1993), lung cancer (Soini et al.,
1993a). malignant bone marrow disease (Soini et al.. 1993b)
and malignant melanoma (Natali et al., 1990). Tenascin has
been isolated from cultured fibroblasts and cultured medium
(Oike et al.. 1990). and tenascin synthesis in fibroblasts is
also induced by tumour growth factor beta (TGF-P) (Pearson
et al., 1988; Erickson and Bourdon, 1989; Chiquet-
Ehrismann, 1990). Therefore. it is thought that tenascin in
tumour tissue is synthesised by stromal fibroblasts, which are
induced by the tumour to produce TGF-P. Tenascin contains
epidermal growth factor-like repeats (Jones et al., 1988), and
it has been suggested that tenascin also has growth-
promoting properties. Furthermore, the adherent growth of
the human colon carcinoma cell line HT-29 can also be
inhibited by a tenascin-containing substrate (Probstmeier et
al., 1990), supporting the theory of a major fibronectin-
antagonising role of tenascin (Chiquet-Ehrismann et al.,
1988). Therefore. an increased amount of tenascin in the
surrounding extracellular matrix is considered to play an
important role in the process of neoplastic transformation,
tumour invasion and metastasis. In this study, tenascin was
expressed in the stromal tissue of gastric cancer but not in
normal tissue, however the expression of tenascin did not
correlate with the depth of tumour invasion, lymph node
metastasis or the prognosis. These results indicate that. in
gastric cancer, the appearance of tenascin is involved in some
way in malignant transformation and tumour progression.
although the positive expression of tenascin does not predict
either the metastatic or aggressive potential of the gastric
cancer. It has been reported that, in colon cancer, tenascin is
more highly expressed in well-differentiated tumours than in
poorly differentiated tumours (Sakai et al., 1993) and, while
the expression of tenascin in gastric cancer also shows the
same tendency, the difference is not statistically significant.
The existence of positive expression of tenascin in normal
gland tissues remains controversial. In the mammary glands.
tenascin has been reported to be prominent in malignant
disease, but it is rare in benign mammary lesions or normal
tissue (Mackie et al., 1987). In contrast, Howeedy et al.
(1990) concluded that tenascin is not a transient extracellular
matrix component restricted to development and transforma-
tion but may be viewed as a consistent, albeit variably dist-
ributed, component of the normal and pathological
periepithelial stromal regions. In colonic tissue, tenascin has
been described in the basement membrane of the mucosal
epithelium, muscularis mucosae and the muscularis propria
of normal adult colon (Oike et al., 1990; Riedl et al., 1992).
And Sakai et al. (1993) reported the distinct localisation of
tenascin in the stroma of tubular adenomas as well as in the
superficial layer of well-differentiated adenocarcinomas; they
also reported an absence of tenascin in normal mucosa.
These discrepancies may be explained by the use of different
kinds of monoclonal antibodies and by differing sensitivity of
the antibody depending on tissue preparation. e.g. frozen
sections of paraffin-embedded sections (Sakai et al., 1993). In
contrast to the controversy surrounding the expression of
tenascin in normal tissue, the expression of tenascin appears
more intense in the stromal tissue of human neoplasms than
in normal tissue. With regard to the stomach, only a few
studies have been carried out (Natali et al., 1991; Ramkis-
soon et al., 1994). In the present study tenascin was expressed
in the muscularis mucosae, the muscularis propria and the
vessel walls of the stomach, but not in the mucosa or sub-
mucosal connective tissue, which is consistent with the
findings of Natali et al. (1991) or Ramkissoon et al.
(1994).
In summary, tenascin appears during the process of either
malignant transformation or tumour progression in gastric
cancer, while the positive expression of tenascin in gastric
cancer is not necessarily considered to indicate clinically
malignant potential such as lymph node metastasis or prog-
nosis.
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